PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $87,226,810 | -37.0% | 5,229,425 | +4.4% | 0.00% | -25.0% |
| Q2 2023 | $138,356,122 | +36.6% | 5,009,273 | +13.8% | 0.00% | +33.3% |
| Q1 2023 | $101,250,991 | +154.1% | 4,402,217 | +20.5% | 0.00% | +200.0% |
| Q4 2022 | $39,845,032 | +36.5% | 3,652,157 | +5.5% | 0.00% | 0.0% |
| Q3 2022 | $29,188,000 | +6.8% | 3,462,384 | +0.2% | 0.00% | 0.0% |
| Q2 2022 | $27,328,000 | -64.4% | 3,454,916 | +6.4% | 0.00% | -50.0% |
| Q1 2022 | $76,868,000 | -31.5% | 3,246,174 | -1.1% | 0.00% | -33.3% |
| Q4 2021 | $112,232,000 | +98.0% | 3,281,636 | +2.6% | 0.00% | +50.0% |
| Q3 2021 | $56,695,000 | -58.5% | 3,199,496 | +5.2% | 0.00% | -50.0% |
| Q2 2021 | $136,459,000 | +75.5% | 3,040,541 | +1.3% | 0.00% | +100.0% |
| Q1 2021 | $77,744,000 | +48.8% | 3,001,629 | +15.8% | 0.00% | 0.0% |
| Q4 2020 | $52,248,000 | +8.8% | 2,591,711 | +5.5% | 0.00% | 0.0% |
| Q3 2020 | $48,013,000 | +33.2% | 2,455,977 | +20.3% | 0.00% | +100.0% |
| Q2 2020 | $36,053,000 | +227.9% | 2,041,460 | +31.1% | 0.00% | 0.0% |
| Q1 2020 | $10,995,000 | -0.2% | 1,557,456 | -0.3% | 0.00% | – |
| Q4 2019 | $11,012,000 | -15.4% | 1,561,957 | +44.2% | 0.00% | -100.0% |
| Q3 2019 | $13,009,000 | +5.6% | 1,083,202 | +6.5% | 0.00% | 0.0% |
| Q2 2019 | $12,321,000 | +258.0% | 1,017,421 | +271.6% | 0.00% | – |
| Q1 2019 | $3,442,000 | +96.2% | 273,789 | +5.1% | 0.00% | – |
| Q4 2018 | $1,754,000 | -28.8% | 260,548 | +8.8% | 0.00% | – |
| Q3 2018 | $2,464,000 | +44.3% | 239,422 | -5.8% | 0.00% | – |
| Q2 2018 | $1,707,000 | -71.1% | 254,035 | -63.0% | 0.00% | – |
| Q1 2018 | $5,904,000 | -42.6% | 687,160 | +39.0% | 0.00% | – |
| Q4 2017 | $10,286,000 | +30.1% | 494,528 | +10.5% | 0.00% | – |
| Q3 2017 | $7,908,000 | +62.1% | 447,525 | +3.7% | 0.00% | – |
| Q2 2017 | $4,879,000 | +10.2% | 431,466 | +24.8% | 0.00% | – |
| Q1 2017 | $4,427,000 | +73683.3% | 345,645 | +131825.6% | 0.00% | – |
| Q4 2016 | $6,000 | – | 262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |